Browsing Tag
RNA interference
2 posts
Can RNA interference expand beyond rare diseases through Tenaya–Alnylam cardiovascular research? (NASDAQ: ALNY, NASDAQ: TNYA)
Tenaya Therapeutics and Alnylam Pharmaceuticals partner to discover RNAi drug targets for cardiovascular disease. Read what this biotech deal could mean.
March 7, 2026
Why Vir Biotechnology’s tobevibart and elebsiran combo may signal a breakthrough in hepatitis delta treatment
Vir Biotechnology’s hepatitis delta therapy shows 66% RNA clearance at 48 weeks. Find out why this could redefine treatment ahead of 2027 trial results.
November 10, 2025